HomeAI · summaries
Storia in 3 fonti
'Practice-Changing' Data Expand Zanidatamab's Approval to Gastroesophageal Cancer
Bispecific antibody plus chemo with or without tislelizumab improves OS, PFS versus trastuzumab
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA approves Ziihera combinations for gastroesophageal adenocarcinoma
The FDA approved two zanidatamab-hrii-based regimens as first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal…
- ·
endpoints.news
FDA approves Jazz's Ziihera in frontline gastric cancer
Jazz's Ziihera wins FDA nod for frontline HER2+ gastric cancer, clearing use with chemo, with or without BeOne's Tevimbra.
